Disparities in colorectal cancer screening among breast and prostate cancer survivors

Abstract

Background Colorectal cancer (CRC) screening is recommended as an integral part of cancer survivorship care. We compared the rates of CRC screening among breast and prostate cancer survivors by primary cancer type, patient, and geographic characteristics in a community‐based health‐care system with a mix of large and small metro urban areas. Materials and Methods Data for this retrospective study were abstracted from medical records of a multi‐specialty practice serving about 250,000 individuals in southern Maryland. Breast (N = 1056) and prostate (N = 891) cancer patients diagnosed prior to 2015 were followed up till June 2018. Screening colonoscopy within the last 10 years was considered to be guideline concordant. Multivariate logistic regression was used to determine the prevalence odds ratios of being concordant on CRC screening by age, gender, race, metro area type, obesity, diabetes, and hypertension. Results Overall 51% of survivors had undergone a screening colonoscopy. However, there was a difference in CRC screening rate between prostate (54%) and breast (44%) cancer survivors. Older age (≥65 years), being a breast cancer survivor compared to prostate cancer, and living in a large compared to small metropolitan area were associated with a lower probability of receiving CRC screening. Having hypertension was associated with higher likelihood of being current on colonoscopy screening guidelines among survivors; but diabetes and obesity were not associated with CRC screening. Conclusions Low levels of CRC screening utilization were found among breast and prostate cancer survivors in a single center in Southern Maryland. Gender, comorbidities, and residential factors were associated with receipt of CRC screening.

Colorectal cancer screening utilization among breast, cervical, prostate, skin, and lung cancer survivors

“…Also, over half of breast cancer survivors received recommended screening for CRC (65%) [ 31 ]. However, our data reports higher level of CRC screening utilization in breast and prostate cancer survivors compared to 44.2% of breast and 54.1% of prostate cancer survivors who had a colonoscopy screening in a multi-specialty practice [ 22 ]. This difference may be attributed to study design and population sample.…”

“…To date, much research regarding CRC screening among cancer survivors predominantly focuses on breast cancer [ 18 – 20 ] or CRC survivors (i.e., reoccurrence of CRC) [ 21 ]. A US study reported that 54% of prostate cancer survivors and 44% of breast cancer survivors received a colonoscopy [ 22 ]. Another study among Singaporean patients reported 46% and 54% of cancer survivors underwent FOBT and colonoscopy, respectively [ 23 ].…”

“…Considering the factors associated with CRC screening uptake, screening behaviors are likely mediated by sociodemographic characteristics (i.e., race/ethnicity, education, income, and rural areas), lifestyle choices (i.e., smoking status and alcohol consumption), family history of CRC, and influenced by health service factors linked to health insurance coverage and physician recommendation [ 20 , 22 , 23 ]. Cancer survivors with higher education, higher household income, family history of CRC, and those with physician recommendation were more likely to receive CRC screening [ 23 , 24 ].…”

Implementing universal upfront multi-gene panel testing in endometrial cancer: From cost to practical considerations

“…Given that a large proportion of EC patients are cured, preventing second cancers is an important target for this population. Several studies have demonstrated low levels of colon cancer screening utilization among cancer survivors [19,20], placing greater risk for the development of second cancer when the diagnosis of LS is missed. Patients with LS have up to a 50% chance of developing a second primary cancer [21] with colorectal cancer being the most common.…”

Indole-Based Tubulin Inhibitors: Binding Modes and SARs Investigations

“…Cancer, a multifaceted, multi-mechanistic and life-threatening disease, is one of the appalling scourges worldwide. Cancer cells are characterized by uncontrollable proliferation, unstoppable differentiation and unpredictable migration [ 1 , 2 , 3 ]. Modern medicine has made great progress in the diagnosis and treatment of cancer.…”